Latham & Watkins represented the underwriters in the transaction. Minerva Surgical, Inc. (Minerva Surgical), a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB),...
Minerva Surgical’s $75 Million Initial Public Offering
Portillo’s Inc.’s $405 Million Initial Public Offering
Latham & Watkins represented the underwriters in the offering. Portillo’s Inc., the fast-casual restaurant concept known for its menu of Chicago-style favorites, has announced the pricing of...
GitLab’s $800 Million Initial Public Offering
Fenwick represented GitLab Inc. on the deal, while Latham & Watkins represented the underwriters. GitLab Inc. (Nasdaq: GTLB), provider of The DevOps Platform, announced its initial public...
Sterling Check Corp.’s $94.4 Million Initial Public Offering
Fried, Frank, Harris, Shriver & Jacobson represented Sterling Check, while Latham & Watkins represented the underwriters in the offering. Sterling Check Corp., a leading provider of...
GE Healthcare’s $1.45 Billion Acquisition of BK Medical
Schiff Hardin advised BK Medical on the deal. Latham & Watkins represented Altaris Capital. GE Healthcare has entered into an agreement to acquire BK Medical, a...
Procept BioRobotics’ $163.9 Million Initial Public Offering
Latham & Watkins represented PROCEPT in the transaction. PROCEPT BioRobotics Corporation, a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology,...
Desktop Metal’s $575 Million Acquisition of ExOne
Latham & Watkins LLP represented Desktop Metal in the transaction. Desktop Metal, Inc. (NYSE: DM) and The ExOne Company (NASDAQ: XONE) have entered into a definitive...
Icosavax’s $209.3 Million IPO
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
Erasca’s $345 Million Initial Public Offering
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
eFFECTOR Therapeutics’ Merger with Locust Walk Acquisition Corp.
Latham & Watkins LLP represented eFFECTOR in the transaction, eFFECTOR Therapeutics, Inc. (eFFECTOR), a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors...
Procore Technologies’ $634 Million Initial Public Offering
Latham & Watkins LLP represented the underwriters in the offering. Procore Technologies, Inc., a leading provider of construction management software, has announced the pricing of its...
Procore Technologies’ $634 Million Initial Public Offering
Latham & Watkins LLP represented the underwriters in the offering. Procore Technologies, Inc., a leading provider of construction management software, has announced the pricing of its...